Additional Description:
An extensive oncology injectable portfolio including albumin-bound paclitaxel, azacitidine, bendamustine, bortezomib, busulfan, carboplatin, carfilzomib, carmustine, cisplatin, cytarabine, dacarbazine, dactinomycin, degarelix, docetaxel, doxorubicin, epirubicin, eribulin, etoposide, fludarabine, fosaprepitant, fulvestrant, gemcitabine, idarubicin, irinotecan, L-asparaginase, leucovorin calcium, melphalan, methotrexate, mitomycin, oxaliplatin, paclitaxel, PEG-L-asparaginase, pemetrexed, plerixafor, topotecan, vinblastine, vincristine, vinorelbine, zoledronic acid and pegfilgrastim injections, plus leuprolide acetate depot injection (3.75/11.25/22.5 mg) and octreotide LAR (20/30 mg) injection.
Leave your rating & comment